Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Lazzarin

Showing results (251-260 of 288) with videos related to

Pageof 29
Sort By:
Lancet (London, England)|April 10, 2007
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsBonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 17, 2016
Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort StudyLars I Gjærde, Leah Shepherd, Elzbieta Jablonowska, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2011
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKJürgen K Rockstroh, Jeffrey L Lennox, Edwin Dejesus, et al.
HIV Clinical Trials|August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRKEdwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.
The New England Journal of Medicine|July 30, 2004
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patientsFrancesca J Torriani, Maribel Rodriguez-Torres, Jürgen K Rockstroh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2010
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJose M Gatell, Christine Katlama, Beatriz Grinsztejn, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 23, 2020
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factorsMarco Ripa, Laura Galli, Andrea Poli, et al.
The New Microbiologica|May 29, 2018
Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessmentMarco Borderi, Gioacchino Angarano, Andrea Antinori, et al.
Lancet (London, England)|August 4, 2009
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L Lennox, Edwin DeJesus, Adriano Lazzarin, et al.
HIV Clinical Trials|June 27, 2006
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendationsMike Youle, Schlomo Staszweski, Bonaventura Clotet, et al.
Pageof 29

Showing results (251-260 of 288) with videos related to

Sort By:
Pageof 29
Lancet (London, England)|April 10, 2007
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsBonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 17, 2016
Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort StudyLars I Gjærde, Leah Shepherd, Elzbieta Jablonowska, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2011
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKJürgen K Rockstroh, Jeffrey L Lennox, Edwin Dejesus, et al.
HIV Clinical Trials|August 2, 2012
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRKEdwin DeJesus, Jürgen K Rockstroh, Jeffrey L Lennox, et al.
The New England Journal of Medicine|July 30, 2004
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patientsFrancesca J Torriani, Maribel Rodriguez-Torres, Jürgen K Rockstroh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2010
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJose M Gatell, Christine Katlama, Beatriz Grinsztejn, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 23, 2020
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factorsMarco Ripa, Laura Galli, Andrea Poli, et al.
The New Microbiologica|May 29, 2018
Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessmentMarco Borderi, Gioacchino Angarano, Andrea Antinori, et al.
Lancet (London, England)|August 4, 2009
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L Lennox, Edwin DeJesus, Adriano Lazzarin, et al.
HIV Clinical Trials|June 27, 2006
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendationsMike Youle, Schlomo Staszweski, Bonaventura Clotet, et al.
Pageof 29